Shared on 22 Oct 25
Fair value Increased 3.97%Analysts Lift Centene Price Target on Margin Recovery but Warn of Lasting Sector Headwinds
Centene's analyst fair value target has been increased from $34.63 to $36.00. Analysts highlight improving margin visibility and constructive EPS guidance updates as key factors supporting the upward revision.
Shared on 08 Oct 25
Fair value Increased 2.03%Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's analyst price target increased from $33.94 to $34.63, as analysts cited stable EPS guidance, anticipated Medicaid margin improvement, and a constructive outlook for Marketplace rates as supporting factors for the revision. Analyst Commentary Recent analyst research on Centene reflects a full spectrum of perspectives, as experts weigh strong execution signals against ongoing uncertainties in the managed care and healthcare exchange landscape.
Shared on 19 Sep 25
Fair value Increased 1.12%Medicaid And Medicare Advantage Will Expand Health Care Access
Centene's modest price target increase reflects mixed analyst sentiment, with optimism around reaffirmed FY25 EPS guidance and Medicaid margin improvements tempered by concerns over ongoing Medicaid and marketplace pressures, regulatory risks, and reduced long-term earnings visibility, resulting in a slight upward revision of fair value to $33.94. Analyst Commentary Bullish analysts cite reaffirmation of FY25 adjusted EPS guidance and constructive commentary on Medicaid margin improvement, ACA Marketplace rate refiling, and Stars performance as supporting recent price target raises.
Shared on 04 Sep 25
Fair value Decreased 2.89%Medicaid And Medicare Advantage Will Expand Health Care Access
Centene’s analyst price target remains at $34.56 as ongoing macro and regulatory uncertainty, elevated Medicaid cost trends, and withdrawn 2025 EPS guidance have driven increased caution and reduced forward earnings visibility. Analyst Commentary Persistent macro uncertainty and regulatory volatility in the healthcare exchange (ACA Marketplace) and Medicaid markets are driving cautious outlooks, especially due to potential disenrollment, risk pool degradation, and rate/trend volatility stemming from legislative changes and the expiration of enhanced APTCs. Centene’s withdrawal of FY2025 EPS guidance, prompted by incorrect Marketplace risk-adjustment assumptions and elevated Medicaid cost trends, has resulted in significant downward revisions to earnings estimates for the next three years.
Shared on 07 May 25
Fair value Decreased 56%Medicaid And Medicare Advantage Will Expand Health Care Access
Shared on 30 Apr 25
Fair value Decreased 5.04%Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 0.84%Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Increased 0.60%Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 0.82%Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 3.81%Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 28%Medicaid And Medicare Advantage Will Expand Health Care Access
AnalystConsensusTarget has decreased future PE multiple from 12.5x to 10.6x.